Anti-HIV Immunotoxins

  • Seth H. Pincus
  • Hua Fang
  • Royce Wilkinson
Chapter

Abstract

The use of targeted therapies to treat infectious diseases is a novel application that requires a persistent infection that cannot be cleared by other means and the expression of microbial antigens on the surface of productively-infected cells. Although some bacterial or parasitic infections may meet these criteria, chronic viral infections and microbe-induced neoplasia are the most likely targets. In this chapter we will discuss the use of immunotoxins to treat human immunodeficiency virus (HIV) infection. The results demonstrate the importance of targeting the appropriate molecules and utilizing the cell biology of the microorganism.

Keywords

Human Immunodeficiency Virus Infected Cell Human Immunodeficiency Virus Infection Pokeweed Antiviral Protein Infected Macaque 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pincus, S. H., and V. V. Tolstikov. Anti-human immunodeficiency virus immunoconjugates. Adv. Pharmacol. 1995; 32: 205.CrossRefGoogle Scholar
  2. 2.
    Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. HIV- 1 dynamics in vivo: Virion clearance rate, infected cell lifespan, and viral generation time. Science 1996; 271: 1582.CrossRefGoogle Scholar
  3. 3.
    Finberg, R. W., S. M. Wahl, J. B. Allen, G. Soman, T. B. Strom, J. R. Murphy, and J. C. Nichols. Selective elimination of HIV-1-infected cells with an interleukin-2 receptor-specific cytotoxin. Science 1991; 252: 1703.CrossRefGoogle Scholar
  4. 4.
    Borvak, J., C.-S. Chou, K. Bell, G. Van Dyke, H. Zola, O. Ramilio, and E. S. Vitetta. Expression of CD25 defines peripheral blood mononuclear cells with productive versus latent HIV infection. J. Immunol. 1995; 155: 3196.Google Scholar
  5. 5.
    McCoig, C., G. Van Dyke, C.-S. Chou, L. J. Picker, O. Ramilo, and E. S. Vitetta. An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro. Proc. Natl. Acad. Sci. USA 1999; 96: 1 1482.Google Scholar
  6. 6.
    Uckun, F. M., K. Bellomy, K. O’Neill, Y. Messinger, T. Johnson, and C.-L. Chen. Toxicity, biological activity, and pharmacokinetics of TXU (Anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with HIV-1. J. Pharmacol. Exp. Ther. 1999; 291: 1301.Google Scholar
  7. 7.
    Chaudhary, V. K., T. Mizukami, T. R. Fuerst, D. J. FitzGerald, B. Moss, I. Pastan, and E. A. Berger. Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature 1988; 335: 369.CrossRefGoogle Scholar
  8. 8.
    Berger, E. A., B. Moss, and I. Pastan. Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART. Proc Natl Acad Sci USA 1998; 95: 1 1511.Google Scholar
  9. 9.
    Pincus, S. H., and J. McClure. Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 1993; 90: 332.CrossRefGoogle Scholar
  10. 10.
    Pincus, S. H., K. Wehrly, R. Cole, H. Fang, G. K. Lewis, J. McClure, A. J. Conley, B. Wahren, M. R. Posner, A. L. Notkins, S. A. Tilley, A. Pinter, L. Eiden, M. Teintze, D. Dorward, and V. V. Tolstikov. In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on the HIV-1 envelope glycoprotein gp160. AIDS Res. Hum. Retrovirus 1996; 12: 1041.CrossRefGoogle Scholar
  11. 11.
    Wild, C., T. Oas, C. McDanal, D. Bolognesi, and T. Matthews. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Nat. Acad. Sci. (USA) 1992; 89: 10537.CrossRefGoogle Scholar
  12. 12.
    Mebatsion, T., S. Finke, F. Weiland, and K. K. Conzelmann. A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell 1997; 90: 841.CrossRefGoogle Scholar
  13. 13.
    Pincus, S. H. Anti-HIV immunotoxins: gp41 rather than gpl 20 should be the target. Int. Antiviral News 1994; 2: 147.Google Scholar
  14. 14.
    Pincus, S. H., K. Wehrly, and B. Chesebro. Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. J. Immunol. 1989; 142: 3070.Google Scholar
  15. 15.
    Pincus, S. H., R. L. Cole, E. M. Hersh, D. Lake, Y. Masuho, P. J. Durda, and J. McClure. In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein. J. Immunol. 1991;146.:4315.Google Scholar
  16. 16.
    Ashorn, P., B. Moss, J. N. Weinstein, V. K. Chaudhary, D. J. FitzGerald, I. Pastan, and E. A. Berger. Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. Proc. Natl. Acad. Sci. USA 1990; 87: 8889.CrossRefGoogle Scholar
  17. 17.
    Ashorn, P., G. Englund, M. A. Martin, B. Moss, and E. A. Berger. Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages. J. Infect. Dis 1991; 163: 703.CrossRefGoogle Scholar
  18. 18.
    Kennedy, P. E., B. Moss, and E. A. Berger. Primary HIV-1 refractory to neutralization by soluble CD4 are potently inhibited by CD4-Pseudomonas exotoxin. Virology 1993; 192: 375.CrossRefGoogle Scholar
  19. 19.
    Pincus, S. H., and K. Wehrly. AZT demonstrates anti-HIV-1 activity in persistently infected cell lines: implications for combination chemotherapy and immunotherapy. J. Infect. Dis. 1990; 162: 1233.CrossRefGoogle Scholar
  20. 20.
    Till, M. A., S. Zolla-Pazner, M. K. Gorny, J. S. Patton, J. W. Uhr, and E. S. Vitetta. Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain. Proc. Natl. Acad. Sci. USA 1989; 86: 1987.CrossRefGoogle Scholar
  21. 21.
    Pincus, S. H., J. McClure, and H. Fang. Use of anti-HIV immunotoxins as probes of the biology of HIV-infected cells. Can. J. Infect. Dis. 1994;5(suppl. A): 23A. Google Scholar
  22. 22.
    Davey, R. T., C. M. Boenning, B. R. Herpin, D. H. Batts, J. A. Metcalf, L. Wathen, S. R. Cox, M. A. Polis, J. A. Kovacs, J. Falloon, R. E. Walker, N. Salzman, H. Masur, and H. C. Lane. Recombinant soluble CD4-pseudomonas exotoxin, a novel immunotoxin, in the treatment of individuals infected with HIV. J. Inf. Dis. 1994; 170. 1180.CrossRefGoogle Scholar
  23. 23.
    Ramachandran, R. V., D. A. Katzenstein, R. Wood, D. H. Batts, and T. C. Merigan. Failure of short-term CD4–PE40 infusions to reduce viral load in HIV infected individuals. J. Inf. Dis. 1994; 170: 1009.CrossRefGoogle Scholar
  24. 24.
    LeMaistre, C. F., S. Rosen, A. Frankel, S. Kornfeld, E. Saria, C. Meneghetti, J. Drajesk, D. Fishwild, P. Scannon, and V. Byers. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood 1991; 78: 1173.Google Scholar
  25. 25.
    Strand, V., P. E. Lipsky, G. W. Cannon, L. H. Calabrese, C. Weisenhutter, S. B. Cohen, N. J. Olsen, M. L. Lee, T. J. Lorenz, and B. Nelson. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis: results of two phase two studies. Arthritis Rheum. 1993; 36: 620.CrossRefGoogle Scholar
  26. 26.
    Amlot, P. L., M. J. Stone, D. Cunningham, J. Fay, J. Newman, R. Collins, R. May, M. McCarthy, V. Ghetie, O. Ramilo, P. E. Thorpe, J. W. Uhr, and E. S. Vitetta. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 1993; 82: 2624.Google Scholar
  27. 27.
    Press, O. W., J. F. Eary, F. R. Appelbaum, P. J. Martin, C. G. Badger, W. B. Nelp, S. Glenn, G. Butchko, D. Fisher, B. Porter, D. C. Matthews, L. D. Fisher, and I. D. Bernstein. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J Med. 1993; 329: 1219.CrossRefGoogle Scholar
  28. 28.
    Allaway, G. P., K. L. Davis-Bruno, G. A. Beaudry, E. B. Garcia, E. L. Wong, A. M. Ryder, K. W. Hasel, M.-C. Gauduin, R. A. Koup, S. McDougal, and P. J. Maddon. Expression and characterization of CD4-IgG2, a novel heteroteramer that neutralizes primary HIV-1 isolates. AIDS Res. Hum. Retroviruses 1995; 11: 533.CrossRefGoogle Scholar
  29. 29.
    Pincus, S. H., T. K. Marcotte, B. M. Forsyth, and H. Fang. In vivo testing of anti-HIV immunotoxins. In Immunotoxin Methods and Protocols, Vol. 166. Methods in Molecular Biology, W. A. Hall, ed. Humana Press, 2001.Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Seth H. Pincus
    • 1
    • 2
  • Hua Fang
    • 1
    • 2
  • Royce Wilkinson
    • 1
    • 2
  1. 1.Department of MicrobiologyMontana State UniversityBozemanUSA
  2. 2.Research Institute for Children, Children’s HospitalLSU Health Sciences CenterNew OrleansUSA

Personalised recommendations